Osage University Partners
 |
|
| Private ownership | |
| Industry | Venture Capital |
| Founded | 2011 |
| Headquarters | Philadelphia, Pennsylvania, United States |
| Website | www |
Osage University Partners (OUP) is a venture capital fund specializing in university spinouts. OUP has partnerships with 80+ affiliated universities, national labs, and research institutions. The fund invests in all stages of development including seed, early, and late stage. General partners include Robert Adelson, Bill Harrington, Marc Singer, and founding partner Louis Berneman. OUP is part of Osage Partners, a family of investment funds with diversified investment strategies including Osage Venture Partners.
Osage University Partners invests across all sectors of university commercialization, including Information Technology, Energy, Materials, and Life Science. The fund invests across all stages, including seed, early, and late. OUP closed its first fund in 2011, a $100 million fund from diverse institutional investors. The fund promotes the venture and entrepreneurship ecosystems around universities, typically co-investing with other leading venture capital firms.
Through their licensing activities, universities and research institutions generally have the right (a “Participation Right”) to invest in their own spin-outs. Historically, few universities or research institutions have exercised such rights. OUP utilizes these rights to invest in university spinouts, and in return universities and research institutions share in the fund’s profits.
OUP seeks to make investments by primarily exercising the Participation Rights of its partner universities, and if no formal Participation Right exists, to participate as a co-investor on behalf of the university or research institution.
Portfolio companies include, Aerie Pharmaceuticals, AGTC, Algorithmia, Ambiq Micro, Aptinyx, Atterocor, Avid Radiopharmaceuticals, Blade Therapeutics, Body Labs, Cancer Guide, Capella Bioscience, Cardioxyl, Cell Design Labs, Clarifai, Cleave Biosciences, Clinipace Worldwide, Corridor Pharmaceuticals, eFFECTOR Therapeutics, Enlibrium, Evolv Technologies, Faraday, Gevo (NASDAQ: GEVO), Guardant Health, Iconic Therapeutics, Immune Design, Infinio, Jibo, Kolltan Pharmaceuticals, Kura Oncology, Kymeta, Liquid Light, Luxtera, Menlo Security, Merganser Biotech, MC10, Millendo Therapeutics, Mirna Therapeutics, Otonomy, Paracosm, Picwell, PMV Pharma, Psikick, Precision Biosciences, Receptos (NASDAQ: RCPT), Ribon Therapeutics, Seismos Technologies, Selecta Biosciences, Sera Prognostics, Skytree, Spero Therapeutics, SolarBridge Technologies, Streetlight Data, Tangent Medical, Urjanet, Virdante Pharmaceuticals, and Voxel8
...
Wikipedia